Puma Biotechnology (NYSE: PBYI) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Puma Biotechnology to related companies based on the strength of its risk, earnings, profitability, institutional ownership, analyst recommendations, valuation and dividends.
Institutional & Insider Ownership
81.0% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 22.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Puma Biotechnology has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Puma Biotechnology’s rivals have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.
Valuation & Earnings
This table compares Puma Biotechnology and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Puma Biotechnology||N/A||-$289.01 million||-15.21|
|Puma Biotechnology Competitors||$207.78 million||-$2.31 million||0.51|
Puma Biotechnology’s rivals have higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations and price targets for Puma Biotechnology and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Puma Biotechnology Competitors||474||2249||6141||119||2.66|
Puma Biotechnology presently has a consensus target price of $124.89, indicating a potential upside of 0.60%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.50%. Given Puma Biotechnology’s stronger consensus rating and higher possible upside, research analysts plainly believe Puma Biotechnology is more favorable than its rivals.
This table compares Puma Biotechnology and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Puma Biotechnology Competitors||-4,697.90%||-120.45%||-44.47%|
Puma Biotechnology Company Profile
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.